Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Interest Expenses (2024)

Summit Therapeutics (SMMT) has disclosed Interest Expenses for 1 consecutive years, with $9000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Interest Expenses changed N/A year-over-year to $9000.0, compared with a TTM value of $9000.0 through Sep 2025, down 99.9%, and an annual FY2024 reading of $8.7 million, down 47.23% over the prior year.
  • Interest Expenses was $9000.0 for Q4 2024 at Summit Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $3.1 million in Q1 2024 and bottomed at $9000.0 in Q4 2024.